BioCentury
ARTICLE | Clinical News

Xerecept corticotropin releasing factor: Interim Phase III data

December 10, 2007 8:00 AM UTC

Interim data from an ongoing, open-label Phase III extension study (501) in 20 evaluable patients showed that daily doses of Xerecept were well tolerated. Nine of the patients discontinued their dexam...